Regenxbio Inc (NASDAQ:RGNX) price on Thursday, April 10, fall -8.46% below its previous day’s close as a downside momentum from buyers pushed the stock’s value to $5.41.
A look at the stock’s price movement, the close in the last trading session was $5.91. Turning to its 52-week performance, $19.38 and $5.03 were the 52-week high and 52-week low respectively. Overall, RGNX moved -18.89% over the past month.
Regenxbio Inc’s market cap currently stands at around $270.97 million, with investors looking forward to this quarter’s earnings report slated for in May.
Analysts have a consensus estimate of 105.35M for the company’s revenue for the quarter, with a low and high estimate of 20M and 132.4M respectively. The average forecast suggests up to a 574.37% growth in sales growth compared to quarterly growth in the same period last fiscal year. Wall Street analysts have also projected the company’s year-on-year revenue to grow to 325.28M, representing a 290.36% jump on that reported in the last financial year.
Turning to the stock’s technical picture we see that short term indicators suggest on average that RGNX is a 50% Sell. On the other hand, the stock is on average a 100% Sell as suggested by medium term indicators while long term indicators are putting the stock in 100% Sell category.
6 analyst(s) have given their forecast ratings for the stock on a scale of 1.00-5.00 for a strong buy to strong sell recommendation. A total of 0 analyst(s) rate the stock as a Hold, 6 recommend RGNX as a Buy and 0 give it an Overweight rating. Meanwhile, 0 analyst(s) rate the stock as Underweight and 0 say it is a Sell. As such, the average rating for the stock is Buy which could provide an opportunity for investors keen on increasing their holdings of the company’s stock.
RGNX’s current price about -24.84% and -24.37% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 34.91, while 7-day volatility ratio is 13.48% and 9.93% in the 30-day chart. Further, Regenxbio Inc (RGNX) has a beta value of 1.21, and an average true range (ATR) of 0.66. Analysts have given the company’s stock an average 52-week price target of $24, forecast between a low of $22 and high of $30. Looking at the price targets, the low is -306.65% off current price level while to achieve the yearly target high, price needs to move -454.53%. Nonetheless, investors will most likely welcome a -343.62% jump to $24 which is the analysts’ median price.
If we refocus on Regenxbio Inc (NASDAQ:RGNX), historical trading data shows that trading volumes averaged 978.79K over the past 3 months. The company’s latest data on shares outstanding shows there are 49.55 million shares.
The 9.82% of Regenxbio Inc’s shares are in the hands of company insiders while institutional holders own 86.31% of the company’s shares. Current price change has pushed the stock -30.01% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the RGNX stock continues to rise going into the next quarter.
